Sanofi managed second quarter sales growth of 6.2 per cent as its diabetes portfolio and growth in emerging markets helped counter the first effects of generic competition for big-selling blood clot prevention drug Plavix. The French pharma firm made
Learn more about it
Related posts:
- Expiring Drug Patents Mean Huge Savings For Millions Of Americans Top drugs getting generic competition by September 2012 are taken...
- Health Store Drug Firm Offer Medicines At 80 Less A popular healthcare chain and the country's leading drug manufacturer...
- Sanofi Files For EU Approval Of Lyxumia A Type 2 Diabetes Agent Partnered Lixisenatide is a once-daily GLP-1 receptor agonist discovered by Zealand...
- Zealand Pharma Announces That Its Partner Sanofi Has Applied For Regulatory Lixisenatide is a once-daily investigational GLP-1 agonist, invented by Zealand...
- Diabetes Drug Actos French Claim Cancer Risk The French drug regulatory authority has suspended use of the...